Shimozuma Kojiro
Dept. of Biomedical Sciences, College of Life Sciences, Ritsumeikan University.
Gan To Kagaku Ryoho. 2019 Jun;46(6):985-989.
Patients' quality of life(QOL)and/or patient-reported outcomes(PRO)has recently been paid much attention as one of the major health outcomes of breast cancer treatments in Japan. In this report, through a systematic literature review for the evidence of QOL/PRO assessments in clinical study undergoing drug treatments of breast cancer in these several years, I introduced the results of the limited qualified papers from 2017. Moreover, I introduced the results of the large multi-center Japanese survey for alopecia induced by chemotherapy in the recent published paper.
患者生活质量（QOL）和/或患者报告结局（PRO）作为日本乳腺癌治疗的主要健康结局之一，最近受到了广泛关注。在本报告中，通过对近年来乳腺癌药物治疗临床研究中QOL/PRO评估证据的系统文献综述，我介绍了2017年有限的合格论文的结果。此外，我还介绍了最近发表的论文中关于日本大型多中心化疗所致脱发调查的结果。
